Streetwise Biotechnology / Pharmaceuticals Articles


Biopharma's Foundation Provides for Downside Protection, Upside Realization

Research Report
  ()
An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate. read more >
News Update

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease

News Update
  ()
The Canadian company continues seeking partners to leverage its discovery and development platform. read more >

Clinical Movement Expected in 2019 on Pharma Firm's 'Gene Therapy Promise'

Research Report
  ()
A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report. read more >

Report Highlights Biopharma's Breakthroughs on Treatment of Life-Threatening Pediatric Liver Diseases

Research Report
  ()
Analyst expects "transformational year" for company with a phase 3 trial underway. read more >

Biopharma's Drug Well Tolerated in Opioid Withdrawal Study

Research Report
  ()
An H.C. Wainwright & Co. discussed these proof-of-concept data and described the company's planned Phase 1 study. read more >

Accelerated Approval Could Be 'Game Changer' for Biotech

Research Report
  ()
This Canadian company's immunotherapeutic targeting ovarian cancer could advance to market sooner, according to a Mackie Research Capital Corp. note. read more >
News Update

Biotech Offers Reason for Others' Failed Trials of Potential Alzheimer's Disease Treatments

News Update
  ()
This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings. read more >

Coverage Initiated on Developer of Therapies for Gastrointestinal Disorders

Research Report
  ()
A ROTH Capital Partners report discussed this U.S.-based biopharma's two assets. read more >

Specialty Pharma 'Advances Pipeline' Ahead of Commercializing Lead Skin Therapy

Research Report
  ()
LifeSci Capital reviewed the key takeaways from this Israeli firm's day-long research and development presentation. read more >

Lessons from January…This Could Make You Money Someday

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research does a deep dive into his portfolio to discern trends and lessons to be learned. read more >

Anixa Doesn't Disappoint

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year. read more >

Early Data for Biotech's Pain Drug Candidate 'Show Promise'

Research Report
  ()
An H.C. Wainwright & Co. report reviewed Phase 1b data for this nonopioid medication being developed for patients with severe pain. read more >

Analyst: Reaction to Trial Data 'Unwarranted'

Research Report
  ()
An analyst's note reviewed the recently announced study results in pancreatic cancer as well as the subsequent decline in stock price. read more >

Analyst Shares 'Revelations from a Pooled Safety Analysis' of Pain Drug

Research Report
  ()
An H.C. Wainwright & Co. report discussed the analgesic's safety profile and how it compares to an on-the-market competitor. read more >

Commercial Launch Planned for Schizophrenia Drug

  ()
A drug used to treat schizophrenic patients will launch commercially in February in the U.S. read more >

Phase 2 Study Begins for German Biopharma's Cancer Drug Candidate

Research Report
  ()
A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated. read more >

Biotech's Flu Vaccine Shows 'Superiority to Market Leader' in Data

Research Report
  ()
Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report. read more >

Biotech Enters License Agreement to Validate Biomarker as Alternative NASH Diagnostic

Research Report
  ()
The background and justification for the deal was covered in an H.C. Wainwright & Co. report. read more >

Potential Tenbagger Biopharma Displays 'Strong Start to New Year'

Research Report
  ()
A ROTH Capital Partners report discussed the recent trial launch and provided upcoming catalysts for the stock. read more >

Texas-Based Biopharma Gets PDUFA Date for Lead Orphan Disease Asset

Research Report
  ()
An H.C. Wainwright & Co. report covered the potential timeline to market and subsequent estimated revenue for this therapeutic, which addresses a rare disorder in collagen production. read more >

Coverage Initiated on Pharma 'Leveraging Large Markets with Differentiated Products'

Research Report
  ()
A Ladenburg Thalmann report outlined the investment thesis for this Colorado-based life sciences firm. read more >

Therapeutics Developer Secures Patents, Continues Phase 3 Trial Planning

Research Report
  ()
An H.C. Wainwright & Co. report provided an update on the Q3/18 activities and achievements of this company targeting NASH. read more >

Coverage Initiated on Vaccine Developer with 'Transformational' Data Expected

Research Report
  ()
A Ladenburg Thalmann report discussed this biotech's late-stage clinical assets in RSV and influenza. read more >

Analyst: Biopharma Makes 'Right Call' in Stopping Combination Agent in Trial

Research Report
  ()
A Mackie Research Capital Corp. note reviewed recent and upcoming developments in this immunotherapy developer's clinical study. read more >

Small-Cap Firm Announces Major Medical Technology Acquisition

Contributed Opinion
  ()
Ron Struthers of Struthers Resource Stock Report profiles an innovative medical firm in Canada that just announced the acquisition of a medical technology firm, a move that will expand its reach across Canada. read more >
Showing Results: 1 to 25 of 74 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts